Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab impact on skin resident memory T cells in atopic dermatitis
2018-004073-27Phase 3Active
- Sponsor
- Alberta Research Chemicals
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of dupilumab in atopic dermatitis (AD) (2 arms), sponsored by Alberta Research Chemicals. Primary endpoint: Primary endpoint: evolution of immune cell populations. Started Mar 2019; status: active.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-004073-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004073-27.